$115.6 M

NERV Mkt cap, 15-Jan-2021
Minerva Neurosciences Net income (Q3, 2020)-8.1 M
Minerva Neurosciences EBIT (Q3, 2020)-8.1 M
Minerva Neurosciences Cash, 30-Sept-202032.5 M
Minerva Neurosciences EV83.3 M

Minerva Neurosciences Income Statement

Minerva Neurosciences Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

18.5m14.3m83.0m26.1m50.2m21.4m

Accounts Receivable

370.0k577.0k

Prepaid Expenses

1.3m1.9m1.2m

Inventories

84.0k1.2m803.2k

Current Assets

19.3m33.5m83.9m129.5m90.0m47.1m

PP&E

50.9k33.5k16.0k

Goodwill

14.9m14.9m14.9m14.9m14.9m14.9m

Total Assets

68.5m82.6m132.9m183.7m139.1m77.5m

Accounts Payable

641.8k1.4m1.5m1.4m1.8m2.3m

Short-term debt

4.0m172.9k

Current Liabilities

3.5m5.3m9.7m6.8m3.6m6.6m

Long-term debt

111.2k

Total Debt

4.0m284.1k

Total Liabilities

27.0m52.1m48.9m49.7m

Common Stock

3.9k3.9k3.9k

Additional Paid-in Capital

126.2m157.1m238.8m296.0m304.8m314.5m

Retained Earnings

(74.7m)(101.8m)(132.9m)(164.4m)(214.6m)(286.7m)

Total Equity

55.3m106.0m131.6m90.3m27.8m

Financial Leverage

1.5 x1.3 x1.4 x1.5 x2.8 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

480.0k23.6m52.2m21.7m16.8m34.8m88.7m91.9m68.9m50.2m36.3m45.1m68.7m87.3m30.6m27.8m37.9m30.0m32.3m32.5m

Prepaid Expenses

33.2k583.5k503.3k309.0k1.2m617.8k278.2k702.4k791.5k421.7k1.1m4.2m3.2m3.7m1.1m1.5m1.4m851.9k542.7k2.4m

Current Assets

513.2k24.2m52.7m35.8m38.8m45.3m97.4m92.6m86.2m78.1m134.1m125.3m111.8m101.4m80.3m70.8m61.4m38.5m35.9m35.0m

PP&E

27.2k35.6k33.7k34.8k30.5k21.9k17.5k13.2k6.3k3.0k330.046.6k42.2k37.8k29.1k24.7k20.4k11.6k7.3k2.9k

Goodwill

15.1m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m14.9m

Total Assets

53.0m73.3m101.8m94.3m89.3m94.4m146.5m141.7m135.3m127.4m193.5m174.5m160.9m150.5m129.8m120.3m110.8m68.8m66.2m65.2m

Accounts Payable

4.3m942.2k1.0m564.3k734.8k1.2m876.5k833.2k3.3m1.4m1.5m2.8m1.3m874.7k3.0m2.9m5.3m3.0m3.1m701.6k

Short-term debt

158.3k1.1m251.6k2.6m3.9m4.8m5.0m5.1m5.2m2.7m1.4m178.8k184.8k157.0k

Current Liabilities

10.1m3.2m4.4m3.8m3.2m7.0m6.2m10.1m13.0m14.6m8.7m7.9m5.0m3.9m6.9m7.6m9.9m7.1m7.4m5.4m

Long-term debt

9.5m8.7m9.6m7.4m6.2m5.0m2.6m1.3m243.1k201.1k157.0k64.4k16.3k

Total Debt

9.7m9.8m9.9m10.0m10.1m9.8m7.6m6.4m5.2m5.4m2.8m243.1k201.1k157.0k243.1k201.1k157.0k

Total Liabilities

23.7m16.6m27.4m25.9m26.3m27.8m25.9m28.6m29.0m29.3m63.3m53.2m50.3m49.1m52.4m53.0m55.3m50.2m9.2m7.2m

Common Stock

852.01.8k2.5k2.5k2.5k2.8k3.5k3.5k3.7k3.7k3.9k3.9k3.9k3.9k3.9k3.9k3.9k3.9k4.1k4.3k

Additional Paid-in Capital

69.4m124.0m155.3m155.8m156.4m176.5m235.6m236.6m249.8m251.3m294.7m298.1m300.0m302.7m307.8m310.1m312.3m317.5m326.3m335.5m

Retained Earnings

(40.1m)(67.3m)(80.8m)(87.4m)(93.4m)(109.8m)(115.0m)(123.5m)(143.5m)(153.3m)(164.5m)(176.8m)(189.3m)(201.3m)(230.4m)(242.9m)(256.8m)(298.9m)(269.4m)(277.5m)

Total Equity

29.2m56.7m74.4m68.4m63.1m66.6m120.6m113.1m106.3m98.0m130.2m121.3m110.7m101.4m77.4m67.3m55.5m18.6m56.9m58.0m

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.8 x1.3 x1.4 x1.4 x1.4 x1.4 x1.2 x1.3 x1.3 x1.3 x1.5 x1.4 x1.5 x1.5 x1.7 x1.8 x2 x3.7 x1.2 x1.1 x

Minerva Neurosciences Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(56.9m)(27.1m)(31.0m)(31.5m)(50.2m)(72.2m)

Depreciation and Amortization

33.9k17.3k16.5k11.1k17.5k17.5k

Accounts Receivable

113.0k113.0k

Inventories

939.0k(400.0k)372.7k

Accounts Payable

368.7k718.8k107.8k(32.7k)364.0k517.3k

Cash From Operating Activities

(36.0m)(24.3m)(25.7m)3.1m(41.9m)(43.4m)

Purchases of PP&E

(52.4k)

Cash From Investing Activities

1.1m(18.3m)17.8m(107.2m)69.5m14.1m

Long-term Borrowings

(4.9m)(4.0m)

Cash From Financing Activities

51.6m38.3m76.6m47.2m(3.3m)525.0k

Net Change in Cash

(56.9m)24.2m(28.8m)

Interest Paid

15.2k616.9k691.2k436.7k92.9k

Minerva Neurosciences Ratios

USDQ2, 2014

Financial Leverage

1.8 x

Minerva Neurosciences Operating Metrics

FY, 2016

Phase I Trials Products

1

Phase II Trials Products

3

Pre-Clinical Phase Products

1